Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria

NCT02040441 is registered in ClinicalTrials.gov with Peter Rossing as lead sponsor.

NCT NCT02040441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02040441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
Lead sponsor
Peter Rossing
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2014
Completion date
November 30, 2018
Enrollment
1,777 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathy, diabetic retinopathy